Brainsway Ltd. (TASE:BRIN) reports positive interim results in the clinical trial of its Deep TMS transcranial magnetic stimulation device for the treatment of bipolar disorder on patients who did not respond to any medications.
The findings are based on the interim report by the chief researcher on the nine patients in the study at the Shalvata Psychiatric Hospital in Israel. The effect of Deep TMS on the patients was measured using different methods for measuring depression, such as the Hamilton Depression Rating Scale (HDRS), and self questionnaires.
The study found that all the patients responded positively to the treatment, compared with previous treatments using antidepressants. There were no complaints or side effects, except for slight headaches that some patients felt after the treatment and which quickly passed.
The chief researcher at Shalvata said that the study was the first evidence that Deep TMS was an effective treatment for bipolar disorder, with the caveat that this was only the beginning.
Brainsway also reported the results of a study on the effectiveness and safety of the use of Deep TMS for the treatment of major depression in cases where patients did not respond to medications. These findings are based on a preliminary report by the chief researcher on 54 patients participating in the trial at Shalvata.
Published by Globes [online], Israel business news - www.globes.co.il - on August 8, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007